drugset / Trial / NCT03290235
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
Non-randomizedParallel-groupOpen-labelTreatment
Summary
1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period 2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2020-10
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEG-somatropin | Protein / enzyme biologic | 0.1 mg/kg | Other |
| Subject | PEG-somatropin | Protein / enzyme biologic | 0.2 mg/kg | Other |
Indications
No indication recorded.